NATCO launches Everolimus tablets, 1 mg

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation

Delhi High Court refuses to restrain Natco from manufacturing spinal muscular atrophy drug

The Court dismissed Swiss drugmaker Roche’s plea for interim injunction

NATCO Pharma updates on acquisition of Adcock Ingram

NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity

NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity

NATCO Pharma API unit in Mekaguda receives EIR from USFDA

The company received one observation in the Form-483

USFDA concludes inspection of NATCO’s Pharma Division, Kothur

The company received seven observations in the Form-483

NATCO Pharma updates on legal proceedings on Risdiplam launch in India

NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court

Natco Pharma appoints Bhimrao Dattu Jadhav as Senior VP – Operations (Formulations) for Pharma Division – Kothur

Jadhav has completed his B.Pharmacy and is having 30+ years of rich experience in operation management in pharmaceutical Industry

NATCO, Lupin receive ANDA approval for Bosentan tablets for oral suspension

TFOS is indicated for the treatment of pulmonary arterial hypertension

NATCO announces approval of its ANDA for Everolimus tablets for Oral Suspension

Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma